Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — H1 FY25 Earnings Presentation
37 slides from Gufic Biosciences's earnings presentation, Nov 14, 2024
Slide 1: Stock exchange cover letter
276/LG/SE/NOV/2024/GBSL November 14, 2024 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 509079 Scrip Symbol: GUFICBIO Subject: Investor Presen
Slide 2: Delivering Care & Cure - Investor Presentation
Delivering Care & Cure Investor Presentation November 2024
Slide 3: Safe Harbor
Safe Harbor This presentation has been prepared by and is the sole responsibility of Gufic Biosc iences Limited (the “ Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions . This prese ntation does not constitute or form part of any offer or invitation
Slide 4: H1 FY25 Business & Financial Highlights
H1 FY25 Business & Financial Highlights
Slide 5: H1 FY25 Business Highlights: Indore Capex Update
H1 FY25 Business Highlights Indore Capex Update: ➢ The Company obtained all requisite licenses, including the FDA license, factory license, Madhya Pradesh Pollution Control Board (MPPCB) consent, as well as approvals for electricity and water connections for its manufacturing facility in Indore by O
Slide 6: H1 FY25 Business Highlights: Criticare Pipeline
H1 FY25 Business Highlights Criticare’s pipeline of products that address key therapeutic gaps and are complex to manufacture Domestic Business Breakup Drug Class Unique Advantages Complexity in Manufacturing Novel β-lactam/β- Targets multi-drug resistant Gram-negative Complex formulation with dual
Slide 7: H1 FY25 Business Highlights: Clinician Empowerment
H1 FY25 Business Highlights Effective Scientific Initiatives for Clinician Empowerment: ➢ Through initiatives like World Sepsis Day campaigns and scientific engagements on judicious antimicrobial use, Gufic actively engages with healthcare professionals to promote best practices in sepsis management
Slide 8: H1 FY25 Business Highlights: Ferticare
H1 FY25 Business Highlights Ferticare: Expanding leadership in assisted reproductive technologies by delivering innovative hormone therapies and specialized support for IVF clinicians and patients Strategy: It centers on addressing critical gaps in assisted reproductive technologies (ART) and offeri
Slide 9: H1 FY25 Business Highlights: Ferticare Pipeline
H1 FY25 Business Highlights Ferticare’s Pipeline and Product Diversification: Ferticare’s product pipeline is designed with a dual strategy: to enhance ART treatment efficacy and to address specific, unmet needs in reproductive health. ➢ Recombinant FSH and HCG: These recombinant hormones offer prec
Slide 10: H1 FY25 Business Highlights: Stellar Division
H1 FY25 Business Highlights Stellar Division: Stellar Division: Strengthening presence in the PPI and pain management segments through targeted product launches, differentiation, and industry engagement ➢ Product Launch Strategy: Stellar has strategically entered high-demand markets like PPI for APD
Slide 11: H1 FY25 Business Highlights: Sparsh
H1 FY25 Business Highlights Sparsh: aims to be a trusted, one-stop partner for smaller hospitals and clinics by providing a comprehensive range of injectables and building direct, meaningful associations with healthcare providers across India Strategy: The Sparsh Division of Gufic Biosciences is str
Slide 12: H1 FY25 Business Highlights: Aesthaderm Study
H1 FY25 Business Highlights Aesthaderm Published Comparative Study in renowned Journal JCAS discussed in H-1 with Customers & various conferences and during workshops. Statistical signifcance reduction in crow’s feet wrinkles by STUNNOX® was observed & found non-inferior to international innovator b
Slide 13: H1 FY25 Business Highlights: Aestherderm
H1 FY25 Business Highlights Aestherderm : Pioneering Category Creation for Botulinum Toxin in India Strategy: Democratizing aesthetic dermatology in India by providing high-quality botulinum toxin solutions, backed by extensive training and clinical research for wider accessibility. The Aestherderm
Slide 14: H1 FY25 Business Highlights: Neurocare
H1 FY25 Business Highlights Neurocare aims to pioneer therapeutic botulinum toxin applications in India by bridging the knowledge gap, fostering clinician expertise, and positioning Zarbot as the trusted, high-quality choice for neurological care Strategy: The Neurocare Division of Gufic Biosciences
Slide 15: H1 FY25 Business Highlights: International Business
H1 FY25 Business Highlights International Business Gufic Biosciences has strategically focused on expanding its footprint in regulated and semi-regulated international markets. This focus is driven by a commitment to high-quality, affordable medicines combined with a robust regulatory compliance str
Slide 16: Research & Development
Research & Development Update on R&D Update on Selvax • Peptides R&D: Paving the Way for In-house Critical • Positive Results from Mouse Studies: API Manufacturing: Our foray into peptides research and development aligns seamlessly with our broader • Selvax conducted comprehensive studies in mice us
Slide 17: Strategic Initiatives
Strategic Initiatives Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Leverage new biological Botulinum Toxin range of Increase market share in technology platform to products through Commercialization of contract manufact
Slide 18: Profit & Loss Statement
Profit & Loss Statement Particulars (in Rs. Crore) Q2 FY25 Q2 FY24 H1 FY25 H1 FY24 FY24 FY23 Total Revenue 204.2 214.9 407.0 409.9 806.7 690.6 EBITDA 38.7 39.7 75.8 76.1 148.05 137.2 EBITDA Margin % 18.95% 18.47% 18.62% 18.57% 18.35% 19.87% Profit before Tax 29.3 30.9 57.4 59.0 115.7 106.7 PBT Margi
Slide 19: Company Overview
Company Overview
Slide 20: About Gufic Biosciences
About Gufic Biosciences Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas BUSINESS STRUCT
Slide 21: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized Injectables Facility Natural Products Facility Lyophilized/Powder Injectables Facility Capability to manufacture Liposomal Amphotericin B and Depot Injections Natura
Slide 22: Upcoming World Class Manufacturing Infrastructure
Upcoming World Class Manufacturing Infrastructure Unit - III at Indore Penem Block UPDATE ON CAPEX Indore Lyophilized/Powder Injectables Dedicated facility for Penem Plant Readiness: The Indore facility is fully operational Facility Carbapenems (Lyophilized / Dry and ready for production, with all n
Slide 23: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and effica
Slide 24: Consolidating the Domestic Branded Business
Consolidating the Domestic Branded Business Products CRITICAL CARE INFERTILITY MASS SPECIALITY 100+ SKU’s Field Force: 250 Field Force: >150 Field Force: >180 200+ Therapy Areas: Antibacterial, Therapy Areas: Hormones, Therapy Areas: Anti Infectives, Antifungal, Pain Management, Recombinant Products
Slide 25: Expanding Creditability in CMO Business
Expanding Creditability in CMO Business Offer CMO services for India and 70+ 150+ Products Reliable CMO service for quality products over a Global Markets Companies across multiple therapy areas decade One of the Largest Supplier of Formulations Liposomal Doxycycline Tigecycline Gonadotropins Micafu
Slide 26: Expanding Geographical Reach
Expanding Geographical Reach 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries) CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZ
Slide 27: Building API Capabilities
Building API Capabilities Special Facility dedicated to API Focused on developing non The categories of API’s infringing, novel, cost manufactured are effective and scalable antifungals, antibacterial, chemical process for APIs, anesthetics and Peptides and Cyclopeptides intermediates for antifungal
Slide 28: Strong Partnership & Licensing Deals
Strong Partnership & Licensing Deals Through our collaborations with global partners that are European leader in IV drug researching to expand the frontiers of pharma and delivery systems. Collaborated biotechnology, Gufic will be a technology bridge to the with Gufic to launch Dual future of health
Slide 29: Extensive Sales, Distribution IT Infrastructure in India
Extensive Sales, Distribution IT Infrastructure in India 2 Central Warehouses Pan India Presence with a located in North Delhi and field force of 1,000+ West Bhiwandi IT Infrastructure Retail coverage of more than 23 Carrying & Forwarding (C&F) agents across India Integrated IT Systems with Sales 1,
Slide 30: Growth Levers
Growth Levers 1 2 3 INTERNATIONAL INDIA BUSINESS CMO BUSINESS BUSINESS • Consolidation of the Critical Care Infertility • Expand our presence in regulated • Scale up the manufacturing capacity business markets such as US EU • Entry into new therapy areas Dermatology - • Consolidation of the clients
Slide 31: Our Robust R&D and Clinical team to augment growth
Our Robust R&D and Clinical team to augment growth Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Ma
Slide 32: Historical Financials
Historical Financials
Slide 33: Historical Financials
Historical Financials Particulars (Rs. Crs.) FY24 FY23 FY22 FY21 FY20 FY19 Total Revenue 808.8 693.2 782.3 491.4 384.6 359.5 EBITDA 148.0 137.2 151.1 87.7 57.9 56.7 EBITDA Margin % 18.3% 19.8% 19.3% 17.8% 15.1% 15.8% Profit before Tax 115.7 106.7 126.8 57.7 30.1 40.2 PBT Margin % 14.3% 15.4% 16.2% 1
Slide 34: Historical Balance Sheet (Equity & Liabilities)
Historical Balance Sheet (Equity & Liabilities) EQUITY & LIABILITIES (Rs. Crs.) Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 10 9.7 9.7 9.7 9.7 7.8 Other Equity 522.5 338.1 259.4 163.7 119.6 67.6 Total Equity 532.5 347.8 269.1 173.4 129.3 75.3 Non-Current Liabilities Financial Liab
Slide 35: Historical Balance Sheet (Assets)
Historical Balance Sheet (Assets) ASSETS (Rs. Crs.) Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, plant and equipment 138.3 126.8 105.5 93.8 72.7 70.3 Intangible assets 5.6 0.7 0.6 0.4 0.6 0.4 Capital work-in-progress 307.1 169.6 40.9 13.4 30.6 9.6 Right of use assets 14.9 3
Slide 36: Historical Cash Flows
Historical Cash Flows Cash Flow Statement (Rs. Crs.) FY24 FY23 FY22 FY21 FY20 FY19 Net Profit Before Tax 115.7 106.7 126.9 57.7 30.1 35.3 Adjustments for: Non - Cash Items / Other Investment or 34.1 29.6 23.2 30.8 24.7 13.4 Financial Items Operating profit before working capital changes 149.8 136.4
Slide 37: Thank You
THANK YOU Company: Gufic Biosciences Limited CIN: L24100MH1984PLC033519 Mr. Avik Das – Investor Relations avik.das@guficbio.com Tel: +91 22 67261000